Breast Cancer
Effector Therapeutics Begins Expansion Cohorts in Zotatifin Trial for Biomarker-Defined Tumors
The firm will open cancer-specific cohorts of HR-positive breast cancer and KRAS-mutated NSCLC patients as a next step in its ongoing Phase I/II clinical trial.
Carrick Therapeutics, Roche Partner for Breast Cancer Combination Trial
The Phase Ib/II trial will evaluate Carrick's CDK7Â inhibitor samuraciclib and Roche's giredestrant in HR-positive, HER2-negative metastatic breast cancer.
Cornell University Licenses UBR5 Inhibitor Program to Bridge Medicines
The New York-based drugmaker will further develop the anti-UBR5 molecules for treatment-resistant TNBC and ovarian cancers
Researchers Look to Validate Promising Immunotherapy Response Biomarker in Early-Stage Breast Cancer
Premium
MHC-II expression could be useful for guiding neoadjuvant immunotherapy in HER2-negative breast cancers, according to findings in Clinical Cancer Research.
Merck's Keytruda Nets Two FDA Full Approvals in Triple-Negative Breast Cancer
The PD-1 inhibitor is now approved as neoadjuvant and adjuvant therapy for high-risk early-stage TNBC, as well as for later-stage, PD-L1-high TNBC patients with chemo.